Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma Clinical Trial
Imaging techniques have considerably improved over the last decades and ocular adnexal
lymphomas (OALs) nowadays can be detected. As major advances in immunophenotyping and
molecular diagnostics in histology have been achieved offering an accurate diagnosis, the
investigators would like to introduce that surgical biopsy of an orbital lymphoma becomes
crucial for the possibility of a correct diagnosis and proper treatment. As radiotherapy
accomplished great preciseness as well and OALs respond excellently to radiation, this
therapy should be the treatment of choice in local defined lymphomas instead of blind
treatment with steroids. Radiation results in great local control rates of 85% to 100%
- Trial with surgical intervention
n/a
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02494700 -
Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT01514344 -
Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma
|
Phase 2 |